The gastrointestinal tract, also known as the digestive tract, is vital to human health. It’s where we digest the food we turn into energy and absorb the nutrients that are essential for our bodies. This is why the sprue-like enteropathy symptoms brought on by the widely prescribed blood pressure medication, Benicar, have disrupted and negatively altered so many lives. Read the rest »
Back in 2002, Benicar was the newest drug to be promoted by its manufacturer, Daiichi Sankyo, as a more effective blood pressure medication than any of its competitors. After receiving approval from the Food and Drug Administration, the company started touting Benicar as a completely safe alternative for patients.
However, more time has passed, more studies have been done on the drug, and more patients continue to report issues when using it. The latest information shows that Benicar can cause some very serious gastrointestinal problems. Read the rest »
Benicar (olmesartan medoxomil) was developed by the Japanese pharmaceutical giant, Daiichi Sankyo, and marketed as a miracle drug for the treatment of hypertension (high blood pressure). But, since its approval by the U.S. Food and Drug Administration (FDA) in 2002, many serious side effects have come to be associated with the medication. Read the rest »
Although the Food and Drug Administration regulates drugs before releasing them to be marketed, thousands of people nationwide, including here in North Carolina, suffer adverse side effects every year. Manufacturers of drugs can be held accountable for injuries caused by an unreasonably dangerous or defective drug. A lawsuit was recently filed against Bayer Healthcare Pharmaceuticals and several other defendants, alleging personal injuries caused by one of the company’s products.
McNeil Consumer Healthcare is currently facing lawsuits regarding one of the most well-known brands of pain relievers — Tylenol. Marketing suggests that the drug is not a harmful drug and that it is the drug most recommended by doctors. What consumers in North Carolina and elsewhere were not told, apparently, concerns potential health risks associated with high dosages.
Joel Rhine Appointed to the Plaintiffs’ Steering Committee (PSC) for the Benicar Multi-District Litigation
Benicar was approved in 2002 for the use by patients with high blood pressure. In the first ten years it was on the market, it was estimated that almost 2 million patients in the United States had been prescribed Benicar. However, in 2012, a link was found between the use of Benicar and the development of sprue-like enteropathy and other serious gastrointestinal conditions.
“They worked hard for me after I was involved in an auto accident. I appreciate their efforts and making me feel like family.”